Research ArticlePulmonary fibrosis

Caveolin-1–derived peptide limits development of pulmonary fibrosis

See allHide authors and affiliations

Science Translational Medicine  11 Dec 2019:
Vol. 11, Issue 522, eaat2848
DOI: 10.1126/scitranslmed.aat2848

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Limiting lung disease

Fibrotic foci that form during idiopathic pulmonary fibrosis (IPF), a type of progressive and fatal interstitial lung disease, alter lung architecture, leading to cell death and loss of lung function. Marudamuthu et al. developed a caveolin-1–derived peptide, CSP7, that inhibited apoptosis of alveolar epithelial progenitor cells and activation of fibrotic lung fibroblasts. When delivered to three mouse models of lung fibrosis, CSP7 reduced extracellular matrix deposition, promoted epithelial cell survival, and improved lung function. CSP7 was also effective when administered ex vivo to lung tissue or cells isolated from people with end-stage IPF. These results support further development of CSP7 as a potential treatment.

View Full Text

Stay Connected to Science Translational Medicine